熱門資訊> 正文

Emergent BioSolutions签署价值3450万美元的疫苗制造和分销协议

2026-04-28 20:42

Emergent BioSolutions Inc.(EBS) 0

Emergent BioSolutions (EBS) entered a ~$34.5M agreement with Substipharm Biologics for JE vaccine manufacturing and distribution.
The deal covers drug substance production for the IMOJEV Japanese Encephalitis vaccine.
Emergent will be the exclusive distributor to the U.S. government pending FDA approval.
Manufacturing will take place at its Canton, Massachusetts facility.
Emergent is scaling up production and plans to hire additional staff.
The agreement supports regulatory submission efforts for U.S. approval of the vaccine.

More on Emergent Biosolutions

Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture
Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript
Emergent BioSolutions Inc. 2025 Q4 - Results - Earnings Call Presentation
Emergent BioSolutions secures $60M contracts
Emergent BioSolutions plummets on weak 2026 revenue guidance, Q4 results

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。